I have been under Dr Verter's care for a couple years after a torn retina. He and his team in Westport have been rockstars! Kudos to all!!! 👏👏👏👏
Trouble Seeing at Night or in Dim Light
What Causes Difficulty Seeing at Night
Several different conditions can impair the ability to see in dim or dark environments. Some are treatable and even reversible, while others require long-term monitoring and management. Understanding the most common causes helps put your symptoms in context.
Retinitis pigmentosa (RP) is a group of inherited retinal diseases in which the rod photoreceptors progressively break down over time. Night vision difficulty is typically the earliest symptom and often appears in childhood or adolescence, depending on the specific form of the disease. As rod cells are lost, patients notice increasing difficulty entering dark rooms, driving at dusk or at night, and navigating in low-light environments.
Over time, peripheral vision also narrows as rod loss extends across the retina. RP affects approximately 1 in 4,000 people in the United States and is the most common inherited retinal dystrophy. Dozens of different gene mutations can cause RP, and the rate of progression varies considerably depending on the specific mutation involved.
Vitamin A plays a critical role in producing rhodopsin, the light-sensitive pigment inside rod photoreceptors that makes low-light vision possible. When vitamin A levels fall too low, the rods cannot make enough rhodopsin to function properly, resulting in night blindness (also called nyctalopia). Vitamin A deficiency is more common in parts of the world with limited dietary variety, but it also occurs in developed countries among people with conditions that impair nutrient absorption.
Conditions such as celiac disease, Crohn's disease, chronic pancreatitis, or a history of certain bariatric surgeries can interfere with adequate vitamin A absorption. Unlike the irreversible rod loss seen in retinitis pigmentosa, night vision problems caused by vitamin A deficiency can often improve significantly with appropriate supplementation under medical supervision.
A cataract is a clouding of the eye's natural lens. This cloudiness reduces the total amount of light reaching the retina and scatters the light that does pass through, both of which worsen vision in dim conditions. Patients with early cataracts often first notice problems with nighttime driving, particularly glare and halos around oncoming headlights.
While cataracts are not a retinal condition, they are a common and treatable cause of night vision difficulty. Cataract surgery removes the clouded lens and replaces it with a clear artificial lens, restoring normal light transmission to the retina. Your retinal specialist will consider cataracts as part of a comprehensive evaluation of your symptoms.
Age-related macular degeneration (AMD) is a disease that affects the macula, the central portion of the retina responsible for sharp, detailed vision. Research has shown that rod photoreceptors in and around the macula can be affected early in the course of AMD, even before other visible signs appear during examination. One early functional sign of AMD is impaired dark adaptation, which is the process by which the eyes adjust from bright conditions to dim ones.
Patients with early AMD may notice that it takes noticeably longer than expected for their vision to adjust when moving from a bright space into a darker room. This rod-mediated dysfunction is an area of active research and may serve as an early indicator of disease progression. If you are over 50 and experiencing delayed dark adaptation, a retinal evaluation is worth discussing with your eye doctor.
Congenital stationary night blindness (CSNB) is a group of inherited conditions in which night vision is impaired from birth but does not worsen over time. Unlike retinitis pigmentosa, CSNB does not cause progressive rod cell loss or narrowing of the visual field. Instead, it results from defects in the way rod photoreceptors transmit their signals to the next layer of neurons in the retina.
Patients with CSNB have stable night vision difficulty throughout their lives and may also have reduced visual sharpness and nearsightedness. The condition is confirmed through electroretinography (ERG), a test that measures the electrical responses of the retina to light, which reveals a characteristic pattern that helps distinguish CSNB from progressive diseases.
Several additional conditions can impair vision in dim light. Advanced glaucoma, a disease of the optic nerve, can reduce peripheral and low-light vision. Panretinal photocoagulation, a laser treatment used for proliferative diabetic retinopathy (abnormal blood vessel growth in the retina caused by diabetes), can reduce night vision as a known side effect because the treatment addresses peripheral retinal tissue. Certain medications, including chloroquine and hydroxychloroquine, can cause retinal toxicity over time that affects rod cell function.
Choroideremia is an inherited condition in which the choroid (the blood-vessel-rich layer beneath the retina) and retinal pigment epithelium progressively break down, producing night vision loss similar to RP. In older patients who develop sudden or rapid night vision changes alongside unusual retinal findings, cancer-associated retinopathy should also be considered. A comprehensive retinal evaluation can help identify which of these conditions is responsible.
When to Seek Urgent Evaluation
Night vision difficulty on its own is rarely an emergency. However, certain combinations of symptoms call for timely or urgent evaluation. Knowing when to act quickly can make a meaningful difference in your outcome.
If night vision difficulty is accompanied by sudden new floaters, flashes of light, or a shadow or curtain appearing anywhere in your visual field, seek evaluation urgently. These symptoms can indicate a retinal tear or detachment, both of which are true ocular emergencies requiring immediate treatment to prevent permanent vision loss.
Rapid onset of night vision difficulty developing over weeks rather than months also warrants prompt evaluation. This pattern can suggest vitamin A deficiency, medication toxicity, or in rare cases, cancer-associated retinopathy. Identifying these causes quickly gives you the best chance for meaningful recovery.
Certain circumstances make night vision difficulty more concerning and increase the urgency of seeking care. A family history of retinitis pigmentosa or another inherited retinal disease is one of the most important risk factors. Patients who have had bariatric surgery or who have gastrointestinal conditions that limit nutrient absorption should be evaluated for vitamin A deficiency if night vision problems develop.
People with diabetes who notice worsening night vision should be assessed for progression of diabetic retinopathy. Patients taking hydroxychloroquine or chloroquine who develop any new visual symptoms, including reduced night vision, should notify both their prescribing physician and their eye doctor promptly.
Gradual difficulty with nighttime driving that has developed over several years in someone with known cataracts is typically related to the cataract and can be addressed at a scheduled appointment. Mild difficulty adjusting to dark environments that has been stable and previously evaluated does not require emergency assessment.
That said, any noticeable worsening of existing night vision difficulty, or the development of new visual symptoms, should be reported to your retinal specialist without delay. Earlier evaluation means more options and a better chance to prevent unnecessary progression.
How We Evaluate Night Vision Problems
When you come to us with night vision difficulty, our evaluation is thorough and personalized. We use a combination of clinical examination and specialized testing to identify the cause and guide the most appropriate care for your situation.
Your specialist will perform a thorough dilated examination, placing drops in your eyes to widen the pupils and allow a clear view of the entire retina. Special attention is paid to the peripheral retina, where rod photoreceptors are most densely concentrated. In retinitis pigmentosa, characteristic findings include bone-spicule pigmentation in the mid-peripheral retina, narrowed retinal blood vessels, and pallor (paleness) of the optic disc.
The macula is also examined for signs of AMD, cystoid macular edema (fluid-related swelling in the central retina), or other conditions that can develop alongside inherited retinal disease. The lens is assessed for cataract formation, which is common in patients with RP.
Visual field testing maps the full extent of your side vision and identifies any areas of vision loss that may not be immediately apparent to you. Goldmann kinetic perimetry is particularly useful for evaluating the pattern and severity of visual field constriction in retinal dystrophies. Humphrey automated perimetry provides detailed measurements of the central visual field.
Repeated visual field tests over time create an objective record of whether your condition is stable or progressing. This information is important for guiding treatment decisions and for evaluating eligibility for emerging therapies.
Electroretinography (ERG) is a specialized test that measures the electrical responses of the retina to flashes of light. It is the most definitive test for evaluating how well the rod and cone photoreceptors are functioning. A full-field ERG records responses from the entire retina and can distinguish between conditions that primarily affect rods, cones, or both cell types.
In retinitis pigmentosa, the ERG shows reduced or absent rod responses, which is diagnostic even in early stages before the retina shows obvious changes on examination. In congenital stationary night blindness, the ERG produces a characteristic pattern that distinguishes it from progressive diseases. ERG results help guide diagnosis, prognosis, and genetic counseling recommendations.
Optical coherence tomography (OCT) produces detailed cross-sectional images of the retinal layers, revealing the extent of photoreceptor preservation or loss. In RP, OCT shows progressive thinning of the outer nuclear layer and loss of the photoreceptor ellipsoid zone, a bright band visible on the scan that corresponds to the healthy inner structure of photoreceptor cells. The width of the preserved ellipsoid zone correlates with remaining visual function and helps track disease progression over time.
Fundus autofluorescence imaging reveals the health of the retinal pigment epithelium (the supportive layer beneath the photoreceptors) and can show a characteristic ring pattern in RP that marks the boundary between functional and degenerating retina. Widefield imaging captures the full extent of peripheral retinal changes that standard imaging may not fully display.
When an inherited retinal disease is suspected, genetic testing can identify the specific gene mutation responsible. This information serves several important purposes: it provides a definitive diagnosis, helps predict the likely course of the disease, and allows for genetic counseling for family members who may be at risk.
Dozens of different genes are associated with retinitis pigmentosa alone, and the specific mutation influences the rate of progression and the pattern of vision loss. Genetic testing also determines eligibility for approved gene therapies and clinical trial programs. We may recommend referral to a genetic counselor to help you and your family understand the results and their implications.
Conditions We May Diagnose
The evaluation process often leads to a specific diagnosis that shapes your long-term care plan. The following are among the most common conditions we identify in patients presenting with night vision difficulty.
RP is confirmed through the combination of clinical findings, ERG results, and often genetic testing. Inherited photoreceptor degenerations as a group affect approximately 1 in 2,000 people and represent a significant cause of vision loss worldwide. The outlook depends heavily on the specific genetic subtype, with some forms progressing slowly over many decades and others causing more significant vision loss earlier in life.
Regular monitoring is essential for patients with RP, both to document the rate of progression and to identify treatable complications that can develop alongside the condition, including cystoid macular edema and cataracts.
Vitamin A deficiency is diagnosed through a blood test and is one of the few fully reversible causes of night blindness. Once supplementation is started and vitamin A levels are restored to a normal range, rod function often improves significantly. We work closely with your primary care physician or gastroenterologist to identify and address the underlying cause of the deficiency, helping to prevent it from recurring.
In patients over 50 who notice difficulty adapting to dim environments, a comprehensive examination may reveal early AMD. OCT and fundus examination often show drusen (small deposits that accumulate beneath the retina) and pigmentary changes consistent with early disease. We will recommend appropriate monitoring and may suggest nutritional supplements based on the AREDS2 formula, a specific combination of vitamins and minerals shown in research to reduce the risk of AMD advancing to a more serious stage.
Home monitoring using an Amsler grid or digital monitoring tools between appointments helps detect meaningful changes early so that new symptoms can be addressed promptly.
Congenital stationary night blindness, choroideremia, and Usher syndrome are among the other inherited conditions that may be identified through clinical examination, ERG patterns, and genetic testing. Usher syndrome, the most common cause of inherited combined hearing and vision loss, includes retinitis pigmentosa as a central feature and affects approximately 1 in 6,000 people worldwide. Each condition has a distinct natural history and genetic basis, making accurate diagnosis essential for appropriate counseling and long-term care planning.
Treatment and Management Options
Treatment depends on the underlying cause of your night vision difficulty. Some conditions have targeted therapies available, while others are managed through monitoring, supportive strategies, and access to emerging research opportunities.
Voretigene neparvovec (Luxturna) is an FDA-approved gene therapy for patients with vision loss caused by mutations in the RPE65 gene, which is associated with certain forms of retinitis pigmentosa and Leber congenital amaurosis (a severe inherited retinal disease that typically appears in infancy or early childhood). The therapy delivers a functional copy of the RPE65 gene directly to retinal cells through a surgical injection beneath the retina. Patients who receive it may experience improved light sensitivity and visual function, including better ability to navigate in dim conditions.
Eligibility requires confirmed mutations in both copies of the RPE65 gene and the presence of sufficient viable retinal cells. Additional gene therapy programs targeting other genetic forms of retinal dystrophy are currently being studied in clinical trials. Our team stays informed about emerging options and will discuss any therapies that may be relevant to your specific diagnosis.
When vitamin A deficiency is the cause of night blindness, supplementation under medical supervision can restore rod function. The specific dosage and duration depend on the severity of the deficiency and its underlying cause. For patients with retinitis pigmentosa, some specialists have recommended vitamin A palmitate supplementation based on studies suggesting it may modestly slow the rate of ERG decline, though this remains an area of ongoing clinical discussion.
Supplementation for RP should only be pursued under the direct guidance of your retinal specialist because excessive vitamin A intake carries health risks, and the potential benefit varies from patient to patient.
When cataracts are contributing to night vision difficulty, surgical removal of the clouded lens and replacement with a clear artificial lens can meaningfully improve vision in dim conditions. For patients who have both cataracts and an underlying retinal condition such as RP, cataract surgery can increase the amount of light reaching the retina and may provide noticeable functional improvement even though the retinal disease itself is not cured.
Your retinal specialist will help evaluate whether surgery is likely to be beneficial and what timing makes the most sense given your individual circumstances.
For night vision loss that cannot be corrected through medical or surgical treatment, low-vision aids and adaptive strategies can meaningfully improve safety and daily independence. Specialized night vision devices that amplify available ambient light can assist with navigation in dim environments. Orientation and mobility training teaches practical techniques for moving safely in low-light conditions.
Improving lighting at home and in the workplace reduces the functional impact of rod cell loss. We can provide referrals to low-vision rehabilitation specialists who focus on helping patients maximize their remaining visual function and maintain their independence.
For progressive conditions such as retinitis pigmentosa, regular monitoring with ERG, OCT, and visual field testing documents the rate of change and helps identify any treatable complications as they arise. Cystoid macular edema, a common complication of RP involving swelling in the central retina, can respond to treatment and, when addressed early, may improve central vision.
Ongoing follow-up also ensures that patients are considered for emerging therapies and clinical trials as they become available. Genetic counseling provides guidance on inheritance patterns and implications for family members. Patient support organizations and peer networks can offer additional resources and community connections for those living with a retinal condition.
Frequently Asked Questions
Here are answers to questions we commonly hear from patients concerned about difficulty seeing at night or in low-light conditions.
Yes, in some situations. If vitamin A deficiency is corrected but the underlying absorption problem is not fully resolved, the deficiency can recur and night vision may worsen again. For patients with progressive inherited retinal diseases, periods of relative stability can still be followed by further decline over time. This is why regular follow-up matters even when symptoms feel unchanged. Catching a new development early gives us more options for intervention before additional vision loss occurs.
The answer depends on the severity of your vision loss and what is causing it. Some patients with mild difficulty can continue driving at night with certain adjustments, while others may reach a point where nighttime driving poses a genuine safety risk to themselves and others. We can assess your functional vision and help you work through this decision. Orientation and mobility specialists can also offer practical strategies for transportation and daily activities if nighttime driving becomes unreliable.
Not necessarily, and the outcome varies significantly from person to person depending on the specific gene mutation involved. Some forms of RP progress very slowly, and many patients retain useful central vision well into adulthood or beyond. Others experience a more rapid course. Accurate genetic testing and regular monitoring give you and your specialist the clearest possible picture of what to expect. We also keep patients informed of emerging treatments and clinical trial opportunities as research continues to advance.
The key warning signs to watch for are sudden flashes of light, a significant new increase in floaters, or a dark shadow or curtain appearing anywhere in your vision. These can indicate a retinal tear or detachment, which requires urgent evaluation and treatment. Night vision difficulty on its own, particularly when it has developed gradually over months or years, is generally not an emergency. If you are ever uncertain about your symptoms, contact your eye care provider and describe what you are experiencing so they can help you decide how quickly you need to be seen.
Yes. Retinitis pigmentosa often begins in childhood or adolescence, with night vision difficulty typically being the first symptom. Children may not always recognize or report the change, especially if it has been present since early in their development. This is why a known family history of retinal disease is an important factor in deciding when to pursue a retinal evaluation for a child. Congenital stationary night blindness is present from birth, so any child who appears to have unusual difficulty in dim light, particularly with a relevant family history, deserves a thorough specialist evaluation.
Expert Retinal Care at New England Retina Associates
If you or a family member is experiencing difficulty seeing at night or in dim light, we encourage you to schedule an evaluation with our team. New England Retina Associates provides comprehensive retinal care from fellowship-trained vitreoretinal specialists at four conveniently located offices throughout Connecticut, welcoming both referred and self-referred patients. Whether your symptoms are longstanding or have only recently appeared, a thorough retinal evaluation is the first step toward understanding what is happening and finding the most appropriate path forward.
30 Years of Care & Commitment
